Allopurinol News and Research

RSS
Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

BioCryst Pharmaceuticals announces BCX4208 compound results for treating gout

FDA approves Krystexxa drug to treat gout

FDA approves Krystexxa drug to treat gout

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences second-quarter total revenues decline to $3.5 million

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst second-quarter total revenues increase to $7.6 million

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Investment report on BioCryst Pharmaceuticals

Investment report on BioCryst Pharmaceuticals

European Congress of Nephrology unveils results of various clinical trials

European Congress of Nephrology unveils results of various clinical trials

Nuon study confirms potential utility of tranilast as uricosuric agent

Nuon study confirms potential utility of tranilast as uricosuric agent

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Allopurinol exhibits potential benefits for CKD patients

Allopurinol exhibits potential benefits for CKD patients

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat

Positive results from Ardea Biosciences' ongoing drug-drug interaction study of RDEA594 and febuxostat